Clinical trial
Quantitative Longitudinal Observation of Neurodegeneration in Patients With Moderate to Advanced Primary Parkinson's Disease Using ¹⁸F-DOPA PET-CT Molecular Imaging and Blood Biomarkers
NCT07919262 is registered in ClinicalTrials.gov with Xuanwu Hospital, Beijing as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Quantitative Longitudinal Observation of Neurodegeneration in Patients With Moderate to Advanced Primary Parkinson's Disease Using ¹⁸F-DOPA PET-CT Molecular Imaging and Blood Biomarkers
- Lead sponsor
- Xuanwu Hospital, Beijing
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- April 30, 2028
- Enrollment
- 36 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
idiopathic parkinson disease
Arms
As registered; 1 arm.
-
Idiopathic Parkinson's Disease Cohort
Patients with moderate to advanced idiopathic Parkinson's disease who will undergo clinical assessments, blood sample collection, and brain PET examinations, with longitudinal follow-up for 1 year.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Change in Putamen 18F-DOPA PET Specific Binding Ratio (SBR) from Baseline to 12 Months
Change in 18F-DOPA PET specific binding ratio (SBR) in the putamen from baseline to 12 months after enrollment. SBR is calculated as the ratio of radiotracer uptake in the putamen to that in a reference region. Higher SBR values indicate greater presynaptic dopaminergic function.
Lead sponsor's other trials
Xuanwu Hospital, Beijing, most recent start first.
+358 more trials See the organization page
Similar trials
Same condition (Parkinson Disease) and phase, most recent start first.
+1,091 more trials See the condition page